Exagen Inc. (XGN) Return on equity 2019–2025
Exagen Inc. (XGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-114.3%FY2025 · since FY2019: -21.6% → -114.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -114.3% | +44.1 pp |
| FY2024 | -158.4% | -54.1 pp |
| FY2023 | -104.4% | +7.2 pp |
| FY2022 | -111.6% | -80.0 pp |
| FY2021 | -31.6% | +8.3 pp |
| FY2020 | -39.9% | -18.3 pp |
| FY2019 | -21.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice